AEON Biopharma logo

AEON BiopharmaNASDAQ: AEON

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 July 2023

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$22.71 M
-93%vs. 3y high
25%vs. sector
-64%vs. 3y high
3%vs. sector
-710%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Mon, 28 Oct 2024 22:00:32 GMT
$1.06+$0.04(+3.92%)

Dividend

No data over the past 3 years
$0.00$164.11 M

Analysts recommendations

Institutional Ownership

AEON Latest News

AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com21 August 2024 Sentiment: POSITIVE

AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
globenewswire.com19 August 2024 Sentiment: POSITIVE

IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
zacks.com29 May 2024 Sentiment: POSITIVE

AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research19 April 2024 Sentiment: POSITIVE

Recently experiencing a decrease in value, AEON Biopharma, Inc. (AEON) has now shown a hammer chart pattern, suggesting that the stock has found a level of support. This, along with an increase in earnings estimate revisions, may result in a potential turnaround for the stock in the near future.

Atalaya Capital Management LP Acquires New Stake in AEON Biopharma Inc
GuruFocus31 July 2023 Sentiment: POSITIVE

Atalaya Capital Management LP (Trades, Portfolio), a New York-based investment firm, recently made a significant acquisition in AEON Biopharma Inc. This article will delve into the details of the transaction, provide an overview of both Atalaya Capital Management LP (Trades, Portfolio) and AEON Biopharma Inc, and analyze the potential impact of this acquisition on the firm's portfolio and the traded company's stock performance.

What type of business is AEON Biopharma?

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

What sector is AEON Biopharma in?

AEON Biopharma is in the Healthcare sector

What industry is AEON Biopharma in?

AEON Biopharma is in the Biotechnology industry

What country is AEON Biopharma from?

AEON Biopharma is headquartered in United States

When did AEON Biopharma go public?

AEON Biopharma initial public offering (IPO) was on 24 July 2023

What is AEON Biopharma website?

https://www.aeonbiopharma.com

Is AEON Biopharma in the S&P 500?

No, AEON Biopharma is not included in the S&P 500 index

Is AEON Biopharma in the NASDAQ 100?

No, AEON Biopharma is not included in the NASDAQ 100 index

Is AEON Biopharma in the Dow Jones?

No, AEON Biopharma is not included in the Dow Jones index

When was AEON Biopharma the previous earnings report?

No data

When does AEON Biopharma earnings report?

The next expected earnings date for AEON Biopharma is 13 November 2024